| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Basic Study |
| Article Title |
Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Carlos A Castaneda, Elizabeth Mittendorf, Sandro Casavilca, Yun Wu, Miluska Castillo, Patricia Arboleda, Teresa Nunez, Henry Guerra, Carlos Barrionuevo, Ketty Dolores-Cerna, Carolina Belmar-Lopez, Julio Abugattas, Gabriela Calderon, Miguel De La Cruz, Manuel Cotrina, Jorge Dunstan, Henry L Gomez and Tatiana Vidaurre |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Carlos A Castaneda, MD, MSc, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, Lima 15038, Peru. carloscastanedaaltamirano@yahoo.com |
| Key Words |
Triple-negative breast cancer; Survival; Tumor-infiltrating lymphocytes; Neoadjuvant therapy |
| Core Tip |
We evaluated a series of 98 triple negative breast cancer cases who received neoadjuvant chemotherapy. Pre-neoadjuvant chemotherapy and post neoadjuvant chemotherapy samples were analyzed. We compared tumor-infiltrating lymphocytes evaluated in whole slides vs in tissue microarray slides. We also compared subsets of tumor-infiltrating-lymphocytes (TILs) evaluated through an absolute counting vs a percentage calculation. Our results confirm the predictive and prognostic role of tumor infiltrating lymphocytes, and evaluated the behavior of tumor infiltrating lymphocytes and lymphocyte subsets during chemotherapy in triple negative breast cancer. Our results increase the understanding of methodological issues for TIL evaluation as well as provide information about variation of the whole TIL population and TIL subpopulation during chemotherapy. |
| Publish Date |
2016-10-08 16:54 |
| Citation |
Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol 2016; 7(5): 387-394 |
| URL |
http://www.wjgnet.com/2218-4333/full/v7/i5/387.htm |
| DOI |
http://dx.doi.org/10.5306/wjco.v7.i5.387 |
